Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.
Location: United States, Maryland, Rockville
Employees: 11-50
Phone: +1 717-327-1822
Total raised: $64.3M
Founded date: 2005
Investors 4
| Date | Name | Website |
| - | Mid Atlant... | bioangels.... |
| - | Johns Hopk... | ventures.j... |
| - | Keiretsu F... | keiretsufo... |
| - | Life Scien... | lsgpa.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.05.2020 | - | $61.3M | - |
| 17.10.2013 | Series B | $3M | - |
Mentions in press and media 20
| Date | Title | Description |
| 14.01.2021 | Immunomic Therapeutics, Inc. announced that it has received $77.72823 million in funding from exax Inc., NEXT SCIENCE Co., Ltd., HLB Co., Ltd. | On January 14, 2021, Immunomic Therapeutics, Inc. closed the transaction. The company amended the terms of the transaction. On the same day, the company has received $16,428,230 in its third tranche, bringing total funding raised in the tra... |
| 01.05.2020 | Immunomic Therapeutics Closes $61.3M Funding | ROCKVILLE, MD, Immunomic Therapeutics announced today the close of a $61.3M financing led by HLB Co., LTD. >> Click here for more funding data on Immunomic Therapeutics >> To export Immunomic Therapeutics funding data to PDF... |
| 30.04.2020 | Immunomic Therapeutics Closes $61.3M Financing | Immunomic Therapeutics, Inc., a Rockville, Md.-based clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, closed a $61.3M financing. The round was led by HLB Co., LTD, a global pharmaceutical co... |
| 23.04.2020 | Immunomic Therapeutics Closes $61.3M Financing | ROCKVILLE, Md.--( BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB C... |
| 19.07.2019 | Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein | Mark McClellan → On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its boar... |
| 15.03.2017 | Immunomic Therapeutics Raises $4.6 Million | A Rockville-based company that is developing treatments for common allergies such as pollen, food and animal has raised $4.6 million in a private debt and security offering, according to a Form D filed by the Securities and Exchange Commiss... |
| 15.03.2017 | Immunomic Therapeutics Raises $4.6 Million | A Rockville-based company that is developing treatments for common allergies such as pollen, food and animal has raised $4.6 million in a private debt and security offering, according to a Form D filed by the Securities and Exchange Commiss... |
| 11.11.2015 | JHU research led to a breakthrough for allergy vaccines. Now they’re taking aim at cancer | Johns Hopkins tech transfer is at the heart of a new agreement meant to bolster the development of a DNA-based vaccine for allergies. Formally, Rockville-based Immunomic Therapeutics inked a licensing deal with Astellas Pharma, which will d... |
| 14.10.2015 | Startups: Astellas on M&A prowl to boost drug pipeline | Japanese pharma giant Astellas is on the prowl to boost its drug pipeline through acquisitions – chasing lower cost, early stage deals in favor of more advanced products thanks to the swelling of biotech valuations in the past three years. ... |
| 17.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $5 million equity raise Joint pain relief CEO: David Renzi Cardero Therapeutics – Sunnyvale, California $891,999 in equity raised of a proposed $1.5 million round Approaching cardiovascular and metabolic disease with a mitochondrial biogene... |
Show more